Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Aug 2;2015(8):CD006849.
doi: 10.1002/14651858.CD006849.pub3.

Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Isuru U Amarasena  1 , Saion Chatterjee, Julia A E Walters, Richard Wood-Baker, Kwun M Fong
Affiliations
Meta-Analysis

Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Isuru U Amarasena et al. Cochrane Database Syst Rev. .

Abstract

Background: Small cell lung cancer (SCLC) is a very fast growing form of cancer and is characterised by early metastasis. As a result, chemotherapy is the mainstay of treatment. A number of different platinum-based chemotherapy regimens and non-platinum-based chemotherapy regimens have been used for the treatment of SCLC, with varying results. This review was conducted to analyse the data from these studies in order to compare their effectiveness.

Objectives: To determine the effectiveness of platinum chemotherapy regimens compared with non-platinum chemotherapy regimens in the treatment of SCLC with respect to survival, tumour response, toxicity and quality of life.

Search methods: We searched the biomedical literature databases CENTRAL (TheCochrane Library 2014, Issue 7), MEDLINE, EMBASE and CINAHL from 1966 to August 2014. In addition, we handsearched reference lists from relevant resources.

Selection criteria: All randomised controlled trials involving patients with pathologically confirmed SCLC (including both limited-stage disease and extensive-stage disease) and the use of a platinum-based chemotherapy regimen in at least one treatment arm and a non-platinum-based chemotherapy regimen in a separate arm.

Data collection and analysis: We used standard methodological procedures expected by the Cochrane Collaboration. Two authors independently assessed search results. We assessed included studies for methodological quality and recorded the following outcome data: survival, tumour response, toxicity and quality of life. We combined the results of the survival, tumour response and toxicity data in a meta-analysis. Quality-of-life data were analysed individually.

Main results: A total of 32 studies involving 6075 patients with SCLC were included in this systematic review. The majority of studies were multi-centre randomised controlled trials conducted throughout Europe, North America and Asia with the earliest study publishing data in 1981 and the latest in 2014. The duration of studies ranged from 12 to 72 months with a median of 32 months. The median age of patients in the vast majority of studies was between 60 and 65 years of age. Eighteen studies presented data on extensive-stage disease. Nine studies presented data on limited-stage disease. Eleven studies did not present data based on the disease stage. These data were analysed separately in subgroup analyses. Sixteen (50%) studies were of good quality with a low risk of bias and the data from these studies were analysed separately in a heterogeneity analysis.There was no statistically significant difference between treatment groups in terms of survival at 6 months, 12 months and 24 months. There was also no statistically significant difference in terms of overall tumour response. However, platinum-based treatment regimens did have a significantly higher rate of complete response. Platinum-based chemotherapy regimens had significantly higher rates of nausea and vomiting and thrombocytopenia toxicity. Four trials presented quality-of-life data, but, due to the different systems used to measure quality of life this data could not be combined in a meta-analysis.

Authors' conclusions: Platinum-based chemotherapy regimens did not offer a statistically significant benefit in survival or overall tumour response compared with non-platinum-based regimens. However, platinum-based chemotherapy regimens did increase complete response rates, at the cost of higher adverse events including nausea and vomiting, anaemia and thrombocytopenia toxicity. These data suggest non-platinum chemotherapy regimens have a more advantageous risk-benefit profile. This systematic review highlights the lack of quality-of-life data in trials involving chemotherapy treatment for SCLC. With poor long-term survival associated with both treatment groups, the issue of the quality of the survival period takes on even more significance. It would be beneficial for future trials in this area to include a quality-of-life assessment.

PubMed Disclaimer

Conflict of interest statement

IUA: none known SC: none known JAEW: none known RWB: none known KMF: none known.

Figures

1
1
Study flow diagram
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Survival by Subgroup
1.1
1.1. Analysis
Comparison 1 Treatment Regimens, Outcome 1 6‐month survival.
1.2
1.2. Analysis
Comparison 1 Treatment Regimens, Outcome 2 12‐month survival.
1.3
1.3. Analysis
Comparison 1 Treatment Regimens, Outcome 3 24‐month survival.
1.4
1.4. Analysis
Comparison 1 Treatment Regimens, Outcome 4 Overall response.
1.5
1.5. Analysis
Comparison 1 Treatment Regimens, Outcome 5 Complete response.
1.6
1.6. Analysis
Comparison 1 Treatment Regimens, Outcome 6 Toxic Death.
1.7
1.7. Analysis
Comparison 1 Treatment Regimens, Outcome 7 Nausea and Vomiting.
1.8
1.8. Analysis
Comparison 1 Treatment Regimens, Outcome 8 Alopecia.
1.9
1.9. Analysis
Comparison 1 Treatment Regimens, Outcome 9 Infection.
1.10
1.10. Analysis
Comparison 1 Treatment Regimens, Outcome 10 Anaemia.
1.11
1.11. Analysis
Comparison 1 Treatment Regimens, Outcome 11 Leukopenia.
1.12
1.12. Analysis
Comparison 1 Treatment Regimens, Outcome 12 Thrombocytopenia.
1.13
1.13. Analysis
Comparison 1 Treatment Regimens, Outcome 13 Granulocytopenia.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Baka 2008 {published data only}
    1. Baka S, Califano R, Ferraldeschi R, Ashcroft L, Thatcher N, Taylor P, et al. Phase III randomised trial of doxorubicin‐based chemotherapy compared with platinum‐based chemotherapy in small‐cell lung cancer. British Journal of Cancer 2008;99(3):442‐7. - PMC - PubMed
Chahinian 1989 {published data only}
    1. Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small‐cell lung cancer by the Cancer and Leukemia Group B. Journal of Clinical Oncology 1989 Aug;7(8):993‐1002. - PubMed
Creech 1982 {published data only}
    1. Creech RH, Stanley K, Vogl SE, Ettinger DS, Bonomi PD, Salazar O. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer Treatment Reports 1982 Jun;66(6):1417‐9. - PubMed
de Jong 2007 {published and unpublished data}
    1. Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, et al. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small‐cell lung cancer. European Journal of Cancer 2007;43:2345–2350. - PubMed
Eagan 1981 {published data only}
    1. Eagan RT, Lee RE, Frytak S, Fleming TR, Ingle JN, Creagan ET, et al. An evaluation of low‐dose cisplatin as part of combined modality therapy of limited small cell lung cancer. Cancer Clinical Trials 1981;4(3):267‐71. - PubMed
Evans 1987 {published data only}
    1. Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D, et al. Superiority of alternating non‐cross‐resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Annals of Internal Medicine 1987 Oct;107(4):451‐8. - PubMed
Farris 1993 {published data only}
    1. Farris A, Bisail M, Sarobba MG, Sanna G, Scotto T, Valzelli S, et al. Cisplatin‐VP16 alternating with cyclophosphamide‐epirubicin versus cyclophosphamide‐epirubicin‐vincristine in small cell lung cancer. Journal of Chemotherapy 1993 Oct;5(5):344‐7. - PubMed
Fukuoka 1986 {published data only}
    1. Fukuoka M, Takada M, Negoro S, Kusunoki Y, Matsui K, Ryu S, et al. Alternating non‐cross resistant chemotherapy for small cell lung cancer. Japanese Journal of Clinical Oncology 1986 Sep;16(3):261‐70. - PubMed
Fukuoka 1991 {published data only}
    1. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small‐cell lung cancer. Journal of the National Cancer Institute 1991 Jun 19;83(12):855‐61. - PubMed
Gatzemeier 1994 {published data only}
    1. Gatzemeier U, Pawel JV, Laumen R, Hossfeld DK, Neuhauss R. Etoposide/vincristine‐based chemotherapy with or without carboplatin in extensive‐stage small cell lung cancer: a prospective randomized phase III trial. Seminars in Oncology 1994 Jun;21(3 Suppl 6):31‐5. - PubMed
Goodman 1990 {published data only}
    1. Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, et al. Treatment of limited small‐cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. Journal of Clinical Oncology 1990 Jan;8(1):39‐47. - PubMed
Greco 2005 {published data only}
    1. Greco FA, Thompson DS, Morrissey LH, Erland JB, Burris HA, Spigel DR, et al. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive‐stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. Oncologist 2005 Oct;10(9):728‐33. - PubMed
Havemann 1987 {published data only}
    1. Havemann K, Wolf M, Holle R, Gropp C, Drings P, Manke HG, et al. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. Cancer 1987 Mar 15;59(6):1072‐82. - PubMed
Jones 1993 {published data only}
    1. Jones AL, Holborn J, Ashley S, Smith IE. CVM versus ACE in the treatment of small cell lung cancer. Oncology 1993 Nov;50 Suppl 2:10‐5. - PubMed
Kanitz 1992 {published data only}
    1. Kanitz E, Kolaric K, Jassem J, Mechl Z, Pawlicki M, Ringwald G, et al. Randomized phase II trial of high‐dose 4'‐epi‐doxorubicin + cyclophosphamide versus high‐dose 4'‐epi‐doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer. Oncology 1992;49(5):327‐32. - PubMed
Lyss 2002 {published data only}
    1. Lyss AP, Herndon JE, Lynch TJ, Turrisi AT, Watson DM, Grethlein SJ, et al. Novel doublets in extensive‐stage small‐cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clinical Lung Cancer 2002 Feb;3(3):205‐10; discussion 11‐2. - PubMed
Postmus 1992 {published data only}
    1. Postmus PE, Splinter TA, Palmen FM, Carney DN, Festen J, Burghouts JT, et al. Comparison of two carboplatin‐containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group. European Journal of Cancer 1992;28(1):96‐100. - PubMed
Postmus 1996 {published data only}
    1. Postmus PE, Scagliotti G, Groen HJ, Gozzelino F, Burghouts JT, Curran D, et al. Standard versus alternating non‐cross‐resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. European Journal Cancer 1996 Aug;32A(9):1498‐503. - PubMed
Quoix 2005 {published data only}
    1. Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F, et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small‐cell lung cancer. Lung Cancer 2005 Aug;49(2):253‐61. - PubMed
Roth 1992 {published data only}
    1. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small‐cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. Journal of Clinical Oncology 1992 Feb;10(2):282‐91. - PubMed
Sculier 1990 {published data only}
    1. Sculier JP, Klastersky J, Libert P, Ravez P, Thiriaux J, Lecomte J, et al. A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party. Annals of Oncology 1990;1(2):128‐33. - PubMed
Sculier 1993 {published data only}
    1. Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G, et al. Multiple‐drug weekly chemotherapy versus standard combination regimen in small‐cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. Journal of Clinical Oncology 1993 Oct;11(10):1858‐65. - PubMed
Sekine 2014 {published data only}
    1. Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, et al. A randomized phase III study of single‐agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive‐disease small‐cell lung cancer. Clinical Lung Cancer 2014;15(2):96‐102. - PubMed
Smith 1991 {published data only}
    1. Smith AP, Anderson G, Chappell G, Bowen DR. Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens. Thorax 1991 Mar;46(3):172‐4. - PMC - PubMed
Souhami 1997 {published data only}
    1. Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al. Five‐day oral etoposide treatment for advanced small‐cell lung cancer: randomized comparison with intravenous chemotherapy. Journal of the National Cancer Institute 1997 Apr 16;89(8):577‐80. - PubMed
Sundstrom 2002 {published data only}
    1. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small‐cell lung cancer: results from a randomized phase III trial with 5 years' follow‐up. Journal of Clinical Oncology 2002 Dec 15;20(24):4665‐72. - PubMed
Urban 1999a {published data only}
    1. Urban T, Baleyte T, Chastang CL, Jeannin L, Delaval P, Zaegel M, et al. Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group. Lung Cancer 1999 Aug;25(2):105‐13. - PubMed
Urban 1999b {published data only}
    1. Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J, et al. The addition of cisplatin to cyclophosphamide‐doxorubicin‐etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. 'Petites Cellules' Group. Cancer 1999 Dec 1;86(11):2238‐45. - PubMed
Veronesi 1994 {published data only}
    1. Veronesi A, Cartei G, Crivellari D, Magri MD, Della Valentina M, Foladore S, et al. Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study. European Journal of Cancer 1994;30A(10):1474‐8. - PubMed
Wampler 1991 {published data only}
    1. Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive‐disease small‐cell lung carcinoma: a Mid‐Atlantic Oncology Program study. Journal of Clinical Oncology 1991 Aug;9(8):1438‐45. - PubMed
White 2001 {published data only}
    1. White SC, Lorigan P, Middleton MR, Anderson H, Valle J, Summers Y, et al. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single‐agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer 2001 Aug 1;92(3):601‐8. - PubMed
Wolf 1987 {published data only}
    1. Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, et al. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small‐cell lung cancer: a multicenter German randomized trial. Journal of Clinical Oncology 1987 Dec;5(12):1880‐9. - PubMed

References to studies excluded from this review

Artel‐Cortes 2004 {published data only}
    1. Artel‐Cortes A, Gomez‐Codina J, Gonzalez‐Larriba JL, Barneto I, Carrato A, Isla D, et al. Prospective randomized phase III trial of etoposide/cisplatin versus high‐dose epirubicin/cisplatin in small‐cell lung cancer. Clinical Lung Cancer 2004 Nov;6(3):175‐83. - PubMed
Blackstock 2005 {published data only}
    1. Blackstock AW, Bogart JA, Matthews C, Lovato JF, McCoy T, Livengood K, et al. Split‐course versus continuous thoracic radiation therapy for limited‐stage small‐cell lung cancer: final report of a randomized phase III trial. Clinical Lung Cancer 2005 Mar;6(5):287‐92. - PubMed
De Marinis 2005 {published data only}
    1. Marinis F, Nelli F, Lombardo M, Ferrau F, Barbera S, Bertetto O, et al. A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first‐line treatment in patients with poor‐prognosis small cell lung carcinoma. Cancer 2005 Feb 15;103(4):772‐9. - PubMed
Eckardt 2006 {published data only}
    1. Eckardt JR, Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, et al. Open‐label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy‐naive patients with extensive‐disease small‐cell lung cancer. Journal of Clinical Oncology 2006 May 1;24(13):2044‐51. - PubMed
Hanna 2006 {published data only}
    1. Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive‐stage disease small‐cell lung cancer. Journal of Clinical Oncology 2006 May 1;24(13):2038‐43. - PubMed
Lara 2006 {published data only}
    1. Lara PN Jr, Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive‐stage small‐cell lung cancer. Clinical Lung Cancer 2006 Mar;7(5):353‐6. - PubMed
McClay 2005 {published data only}
    1. McClay EF, Bogart J, Herndon JE, Watson D, Evans L, Seagren SL, et al. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited‐stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). American Journal of Clinical Oncology 2005 Feb;28(1):81‐90. - PubMed
Niell 2005 {published data only}
    1. Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony‐stimulating factor in patients with extensive‐stage small‐cell lung cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology 2005 Jun 1;23(16):3752‐9. - PubMed
Paccagnella 2004 {published data only}
    1. Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004 Jan;43(1):83‐91. - PubMed
Pathak 2005 {published data only}
    1. Pathak AK, Bhutani M, Guleria R, Bal S, Mohan A, Mohanti BK, et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. Journal of the American College of Nutrition 2005 Feb;24(1):16‐21. - PubMed
Schild 2004 {published data only}
    1. Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, et al. Long‐term results of a phase III trial comparing once‐daily radiotherapy with twice‐daily radiotherapy in limited‐stage small‐cell lung cancer. International Journal of Radiation, Oncology, Biology, Physics 2004 Jul 15;59(4):943‐51. - PubMed
Seifart 2005 {published data only}
    1. Seifart U, Jensen K, Ukena J, Mueller C, Schroder M, Fuhr HG, et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer 2005 Jun;48(3):415‐22. - PubMed

Additional references

Abeloff 2004
    1. Abeloff MD. Clinical oncology. 3rd Edition. Philadelphia, Pa: Elsevier Churchill Livingstone, 2004.
ACN 2004
    1. ACN. Clinical practice guidelines for the prevention, diagnosis and management of lung cancer. Clinical practice guidelines for the prevention, diagnosis and management of lung cancer. Sidney: Cancer Council Australia, 2004.
Alberg 2003
    1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest Jan 2003;123(1 Suppl):21S‐49S. - PubMed
Cella 2002
    1. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, et al. What is a clinically meaningful change on the FACT‐L Questionnaire? Results of ECOG study 5592. J Clin Epidemiology 2002;55(3):285‐95. - PubMed
Chabner 2010
    1. Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner, Cancer Chemotherapy and Biotherapy). 5. LWW, December 2010.
Chan 2013
    1. Chan BA, Coward JI. Chemotherapy advances in small‐cell lung cancer. Journal of Thoracic Disease October 2013;5(Supplement 5):S565‐S578. - PMC - PubMed
Dela Cruz 2011
    1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clinics in Chest Medicine December 2011;32(4):605‐644. - PMC - PubMed
Evans 1986
    1. Evans WK, Feld R, Murray N, Pater J, Shelley W, Willan A, et al. The use of VP‐16 plus cisplatin during induction chemotherapy for small‐cell lung cancer. Seminars in Oncology 1986;13(3 (Suppl 3)):10‐6. - PubMed
Glisson 2014
    1. Glisson BS, Byers LA. Pathobiology and staging of small cell carcinoma of the lung. UpToDate. Waltham, MA: UpToDate, Nov 2014.
Gralla 2004
    1. Gralla RJ. Quality‐of‐life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist 2004;9 Suppl 6:14‐24. - PubMed
Gusi 2010
    1. Gusi N, Olivares PR, Rajendram R. The EQ‐5D Health‐Related Quality of Life Questionnaire. Handbook of Disease Burdens and Quality of Life Measures. Springer New York, 2010:87‐99.
Heintz 2010
    1. Heintz NH, Janssen‐Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. American Journal of Respiratory Cell and Molecular Biology Feb 2010;42(2):133‐139. - PMC - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011a
    1. Higgins JPT, Deeks JJ (editors). Chapter 7. Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley & Sons for The Cochrane Collaboration..
Higgins 2011b
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011c
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration.
Le Pechoux 2004
    1. Pechoux C, Dhermain F, Bretel JJ, Laplanche A, Dunant A, Tarayre M, et al. Modalities of radiotherapy in small cell lung cancer: thoracic radiotherapy and prophylactic cerebral irradiation. Revue de Pneumologie Clinique 2004;3S:91‐103. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Micke 2002
    1. Micke P, Faldum A, Metz T, Beeh K‐M, Bittinger F, Hengstler J‐G, Buhl R. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer ‐ what limits limited disease?. Lung Cancer September 2002;37(3):271‐276. - PubMed
Park 2003
    1. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Japanese Journal of Clinical Oncology September 2003;33(10):533‐537. - PubMed
Peckham 1995
    1. Peckham MJ, Pinedo HM, Veronesi U. Oxford Textbook of Oncology. Oxford University Press, 1995.
Pujol 2000
    1. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small‐cell lung cancer? A meta‐analysis of randomized trials of a cisplatin‐containing regimen versus a regimen without this alkylating agent. British Journal of Cancer 2000;83(1):8‐15. - PMC - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Stinchcombe 2010
    1. Stinchcombe TE, Gore EM. Limited‐Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms. The Oncologist Feb 2010;15(2):187‐195. - PMC - PubMed
Stubblefield 2009
    1. Stubblefield M, O'Dell M. Cancer Rehabilitation: Principles and Practice. New York City: Demos Medical Publishing, Apr 22, 2009.
WHO 1979
    1. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset publication no 48.. Geneva, Switzerland: World Health Organization, 1979.

References to other published versions of this review

Amarasena 2008
    1. Amarasena IU, Walters JA, Wood‐Baker R, Fong K. Platinum versus non‐platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic Reviews 2008, Issue Oct 8;(4):CD006849. [DOI: 10.1002/14651858.CD006849.pub2] - DOI - PubMed

Publication types

MeSH terms

Substances